Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Spruss

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Pharmaceutical Development and Technology|April 1, 2003
Monolithic triglyceride matrices: a controlled-release system for proteinsW Vogelhuber, E Magni, M Mouro, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1992
Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1)D Grimm, F Hofstädter, J Bauer, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 4, 2000
Establishment and characterization of the follicular thyroid carcinoma cell line ML-1J Schönberger, J Bauer, T Spruss, et al.
Archiv Der Pharmazie|February 1, 1992
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3G Bernhardt, R Müller, R Gust, et al.
Archiv Der Pharmazie|May 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting propertiesH Reile, T Spruss, R Müller, et al.
The Prostate|January 1, 1989
[1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activityM R Schneider, C D Schiller, A Humm, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 5, 2001
Programmable biodegradable implantsW Vogelhuber, P Rotunno, E Magni, et al.
Gut|September 21, 2007
The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinomaC Hellerbrand, T Amann, J Schlegel, et al.
Archiv Der Pharmazie|July 10, 1999
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studiesG Bernhardt, M Koch, T Spruss, et al.
Archiv Der Pharmazie|May 31, 2001
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic propertiesS Schertl, R W Hartmann, C Batzl-Hartmann, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Pharmaceutical Development and Technology|April 1, 2003
Monolithic triglyceride matrices: a controlled-release system for proteinsW Vogelhuber, E Magni, M Mouro, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1992
Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1)D Grimm, F Hofstädter, J Bauer, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 4, 2000
Establishment and characterization of the follicular thyroid carcinoma cell line ML-1J Schönberger, J Bauer, T Spruss, et al.
Archiv Der Pharmazie|February 1, 1992
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3G Bernhardt, R Müller, R Gust, et al.
Archiv Der Pharmazie|May 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting propertiesH Reile, T Spruss, R Müller, et al.
The Prostate|January 1, 1989
[1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activityM R Schneider, C D Schiller, A Humm, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 5, 2001
Programmable biodegradable implantsW Vogelhuber, P Rotunno, E Magni, et al.
Gut|September 21, 2007
The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinomaC Hellerbrand, T Amann, J Schlegel, et al.
Archiv Der Pharmazie|July 10, 1999
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studiesG Bernhardt, M Koch, T Spruss, et al.
Archiv Der Pharmazie|May 31, 2001
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic propertiesS Schertl, R W Hartmann, C Batzl-Hartmann, et al.
Pageof 5